Real-World Study Shows Effectiveness of Ixekizumab for Psoriasis
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 28, 2025 -- For patients with moderate-to-severe plaque psoriasis, ixekizumab is effective and safe, with induction therapy enhancing initial response, according to a study published online Jan. 29 in the Journal of Clinical Medicine.
Ricardo Ruiz-Villaverde, M.D., Ph.D., from Hospital Universitario San Cecilio in Granada, Spain, and colleagues conducted a multicenter, observational study involving 183 patients with moderate-to-severe plaque psoriasis to examine the real-world effectiveness, safety, and drug survival of ixekizumab with and without an induction phase. Patients were divided into an induction group (160 mg at baseline, followed by 80 mg every two weeks through 12 weeks, then every four weeks) and a noninduction group (80 mg every four weeks from initiation).
Baseline Psoriasis Activity Skin Index (PASI) and Physician Global Assessment scores were higher in the induction group, indicative of greater disease severity. The researchers observed significant clinical improvements with both regimens, with faster initial responses in the induction group. Lower drug survival was seen in the induction group, possibly due to higher baseline disease burden and severity. Comorbidities were prevalent, especially in the induction group, and included metabolic syndrome, cardiovascular risks, and psychiatric conditions.
"While induction therapy appears to enhance initial PASI responses, meaningful long-term improvements can also be achieved without induction, particularly in patients with lower baseline disease activity," the authors write. "These findings underscore ixekizumab's versatility and durability as a therapeutic option, even in treatment-experienced populations."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Central Adiposity Measures Associated With Psoriasis Risk
TUESDAY, June 3, 2025 -- Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a research letter published...
Psoriasis Tied to Increased Risk for Sleep Disorders
MONDAY, June 2, 2025 -- Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according to a study published online...
Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics
WEDNESDAY, May 21, 2025 -- For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.